According to Timer analysis, PLAGL2 was upregulated in bladder, breast, cervix, bile ducts, colorectal, esophagus, kidney, liver, lung, stomach, and CNS cancer compared with normal cases (Figure 1A, Supplementary Table S1), whereas it was downregulated in renal and thyroid cancers. Here, PLAGL2 is linked to thyroid gland carcinoma.